利柏特(605167.SH):簽訂《寧德二期5BDA、7BUG模塊建造安裝工程及臨時泊位工程合同》
格隆匯3月19日丨利柏特(605167.SH)公佈,公司於2025年2月14日在上海證券交易所網站披露了《江蘇利柏特股份有限公司關於重大項目中標的公告》,公司全資子公司上海利柏特工程技術有限公司(簡稱“利柏特工程”)收到中廣核工程有限公司(簡稱“中廣核工程”)出具的《中標通知書》,確認利柏特工程中標“寧德二期5BDA、7BUG模塊建造安裝工程及臨時泊位工程”項目。近日,利柏特工程與中廣核工程簽訂了《寧德二期5BDA、7BUG模塊建造安裝工程及臨時泊位工程合同》,本次合同簽訂屬於公司日常經營範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.